Question: is alnylam an acquisition target?
Answer: Alnylam, though a relatively smaller biotech compared to the previous four, has become a hot acquisition target after approval of its key pipeline candidate, Onpattro (patisiran) in the United States and Europe this year. The market cap of Alnylam is around $8 billion.